- Framework of problems / Transparent
- Funding or sponsor of systematic review not reported
- A review found heterogeneous approaches and insufficient reporting in overviews on adverse events
Ref ID | 905 |
First Author | T. Sachse |
Journal | JOURNAL OF CLINICAL EPIDEMIOLOGY |
Year Of Publishing | 2022 |
URL | https://www.sciencedirect.com/science/article/pii/S0895435622001925?via%3Dihub |
Keywords |
Harms Pharmacological Low reporting quality Overlapping reviews/redundancy Certainty Overviews/Umbrella Reviews |
Problem(s) |
Lack of guidance or consistency in systematic overview / umbrella / review of systematic reviews Methods not described to enable replication Reasons for excluding potentially eligible studies not provided Funding or sponsor of systematic review not reported Individual study characteristics not reported sufficiently |
Number of systematic reviews included | 27 |
Summary of Findings | From 27 included systematic overview reviews of adverse (drug-associated) events (AEs) of pharmacological interventions indexed across MEDLINE, Embase, Epistemonikos, and the Cochrane Database of Systematic Reviews from inception to May 17, 2021. The median number of included systematic reviews in each overview was 15 (interquartile range 7–34). Study selection methods were reported in 52%, methods for data extraction in 67%, and methods for critical appraisal in 63% of overviews. An assessment of methodological quality of included systematic reviews was performed in 70% of overviews. Only 22% of overviews reported strategies for dealing with overlapping systematic reviews. An assessment of the certainty of the evidence was performed in 33% of overviews. |
Did the article find that the problem(s) led to qualitative changes in interpretation of the results? | Not Applicable |
Are the methods of the article described in enough detail to replicate the study? | Yes |